- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00276575
Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors
Phase I Study of Bevacizumab in Combination With Everolimus and Erlotinib in Advanced Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Erlotinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and everolimus may also block blood flow to the tumor. Giving everolimus and erlotinib together with bevacizumab may kill more tumor cells.
PURPOSE: This randomized phase I trial is studying the side effects and best dose of erlotinib and everolimus when given together with bevacizumab in treating patients with advanced solid tumors.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
OBJECTIVES:
Primary
- Estimate the maximum tolerated dose (MTD)/recommended phase II regimen of everolimus and erlotinib hydrochloride when given with bevacizumab in patients with advanced solid tumors.
- Evaluate safety of bevacizumab, everolimus, and erlotinib hydrochloride in these patients.
Secondary
- Describe the impact of this combination therapy on dermal wound angiogenesis and inhibition of vascular endothelial growth factor receptor 1 (VEGFR1), mTOR/p70S6K, and other related markers in granulation tissue.
- Evaluate clinical activity (partial response, complete response, or stable disease > 6 months) associated with this regimen.
OUTLINE: This is a dose-escalation study followed by a randomized study.
- Part 1: Patients receive bevacizumab IV on days 1 and 15 and oral everolimus and oral erlotinib hydrochloride* once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of patients receive escalating doses of everolimus or escalating doses of everolimus and erlotinib hydrochloride* until the maximum tolerated dose (MTD) is determined. Patients in part 2 of the study are treated at the MTD of everolimus and erlotinib hydrochloride.
NOTE: *The first cohort of patients receive bevacizumab and everolimus only until the MTD is determined, the subsequent cohorts of patients receive bevacizumab, everolimus, and erlotinib hydrochloride
Part 2: Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral everolimus once daily beginning on day 1, oral erlotinib hydrochloride once daily beginning on day 15, and bevacizumab IV once every 2 weeks beginning on day 15. Treatment continues in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive oral erlotinib hydrochloride once daily beginning on day 1, oral everolimus once daily beginning on day 15, and bevacizumab IV once every 2 weeks beginning on day 15. Treatment continues in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27710
- Duke Comprehensive Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
DISEASE CHARACTERISTICS:
Histologically confirmed malignancy
- Metastatic or unresectable disease
- Standard curative or palliative measures do not exist OR are no longer effective
- No CNS metastases
- No centrally-located non-small cell lung cancer
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Leukocytes ≥ 3,000/mm³
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST/ALT ≤ 2.5 times ULN (5 times ULN if known hepatic metastases)
- Urine protein to creatinine ratio ≤ 1.0 OR urine protein < 1 g by 24 hour urine collection
- Creatinine clearance ≥ 50 mL/min OR creatinine normal
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during study and for up to 4 months after study treatment has stopped
- No uncontrolled hypertriglyceridemia (i.e., fasting serum triglyceride > 350 mg/dL)
- No uncontrolled hypercholesterolemia (i.e., fasting serum cholesterol > 300 mg/dL)
- No poorly controlled hypertension (i.e., blood pressure > 160/100 mm Hg)
- No poorly controlled or clinically significant atherosclerotic vascular disease
- No thrombosis within 6 months
- No venous thromboembolic event within 6 months
- No arterial thromboembolic events within 12 months
- No cerebrovascular accident or transient ischemic attack in past 12 months
- No myocardial infarction or unstable angina in past 12 months
- No clinically significant peripheral vascular disease in past 12 months
No New York Heart Association class II-IV congestive heart failure
- Atrial or supraventricular tachycardias well controlled with beta blocker or calcium channel blocker allowed
- Chronic pacemaker use allowed
- No serious cardiac arrhythmia requiring medication
- No other clinically significant cardiovascular disease
- No hemoptysis > 1 tablespoon within 6 months
- No presence of bleeding diathesis
- No coagulopathy
- No presence of significant gastrointestinal (GI) disorders that would affect drug absorption
- No hemodynamically significant GI bleeding
- No history of intolerance to bevacizumab, everolimus, or erlotinib
- No other major bleeding event
- No ongoing or active infection
- No psychiatric illness or social situations that would limit safety or compliance with study requirements
- No other uncontrolled intercurrent illness
PRIOR CONCURRENT THERAPY:
- No angioplasty or cardiac or vascular stenting within the past 12 months
- No major surgery within past 28 days
- No other investigational agents within past 28 days
- No chemotherapy for cancer within past 21 days
- No biologic therapy for cancer within past 21 days
- No radiation therapy for cancer within past 21 days
- No hormonal therapy for cancer within past 21 days
- No minor surgical procedures within past 14 days
- No concurrent antiplatelet agents other than aspirin < 325 mg/day
- No use of statin drugs other than pravastatin or atorvastatin
- Initiation of blood pressure (BP) medication is permitted prior to study entry provided that BP < 150/90 mm Hg on 3 measurements over one week (study day -7 to 1) before starting treatment
- No concurrent grapefruit juice
No concurrent therapeutic anticoagulation
- Prophylactic low-dose anticoagulation for indwelling catheters is permitted
No concurrent administration of any of the following drugs:
- Nicardipine
- Verapamil
- Clotrimazole
- Fluconazole
- Itraconazole
- Ketoconazole
- Clarithromycin
- Erythromycin
- Troleandomycin
- Cisapride
- Metoclopramide
- Bromocriptine
- Cimetidine
- Danazol
- HIV-protease inhibitors (e.g., ritonavir, indinavir)
- Hypericum perforatum (St. John's wort)
- Carbamazepine
- Phenobarbital
- Phenytoin
- Diltiazem
- Rifabutin
- Rifapentine
- Rifampin
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Bevacizumab, Everolimus, and Erlotinib
Dose Level Dose Bevacizumab (mg/kg q2wks) Everolimus (mg daily) Erlotinib (mg daily) -1 5 5 ---
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Maximum Tolerated Dose
Lasso di tempo: Until study completion
|
Its primary objective is to estimate the MTD/recommended phase II dose combination or regimen
|
Until study completion
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Safety
Lasso di tempo: Until study completion
|
endpoints will be evaluated in an exploratory fashion
|
Until study completion
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Herbert I. Hurwitz, MD, Duke Cancer Institute
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Agenti antineoplastici
- Agenti immunosoppressivi
- Fattori immunologici
- Agenti antineoplastici, immunologici
- Inibitori dell'angiogenesi
- Agenti di modulazione dell'angiogenesi
- Sostanze per la crescita
- Inibitori della crescita
- Inibitori della chinasi proteica
- Erlotinib cloridrato
- Bevacizumab
- Everolimo
Altri numeri di identificazione dello studio
- Pro00008048
- DUMC-6026-05-6R1
- GENENTECH-DUMC-6026-05-6R1
- NOVARTIS-DUMC-6026-05-6R1
- CDR0000449970 (Altro identificatore: NCI)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su everolimus
-
Novartis PharmaceuticalsCompletatoTumore neuroendocrino gastroenteropancreatico del sistema polmonare o gastroenteropancreaticoGermania
-
Novartis PharmaceuticalsTerminatoCarcinoma epatocellulareHong Kong, Taiwan, Tailandia
-
The Netherlands Cancer InstituteAttivo, non reclutanteCarcinomi neuroendocriniOlanda
-
German Breast GroupNovartisTerminatoCancro al seno metastaticoGermania
-
German Breast GroupNovartisCompletatoCancro al seno | Tumore positivo al recettore ormonaleGermania
-
Guangdong Provincial People's HospitalNovartisSconosciutoTumori neuroendocrini | Tumore carcinoideCina
-
Novartis PharmaceuticalsTerminatoCarcinoma, cellule renaliAustralia, Corea, Repubblica di
-
Centre Leon BerardSospeso
-
University of LuebeckTerminatoDisfunsione dell'arteria coronariaGermania
-
Abbott Medical DevicesCompletatoAterosclerosi | Malattia vascolare perifericaGermania, Austria, Belgio, Italia